We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
21
11 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2010
Active, not recruiting
11
52.4%
Completed
6
28.6%
Recruiting
4
19.1%
No approval data available
- Otsuka Pharmaceutical has acquired worldwide rights to Cantargia's CAN10, an IL-1RAP targeting monoclonal antibody in Phase 1 development for autoimmune diseases, for $33 million upfront. - The deal includes potential milestone payments up to $580 million plus double-digit tiered earn-out payments from global product sales, with transaction expected to close in Q3 2025. - CAN10 uniquely inhibits multiple IL-1 family cytokines (IL-1, IL-33, and IL-36) simultaneously by targeting IL-1RAP, potentially offering next-generation treatment for inflammatory and autoimmune conditions. - The acquisition expands Otsuka's autoimmune disease pipeline and leverages their antibody drug platform through subsidiary Visterra to accelerate development across multiple therapeutic pathways.
